Chiral phosphines for palladium-catalyzed asymmetric α-arylation of ester enolates to produce tertiary stereocenters in high enantioselectivity

US9512155B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9512155-B2
Application numberUS-201214239541-A
CountryUS
Kind codeB2
Filing dateAug 17, 2012
Priority dateAug 19, 2011
Publication dateDec 6, 2016
Grant dateDec 6, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The disclosure provides new and improved methods for the Pd-catalyzed asymmetric α-arylation of ester compounds, which produce the corresponding α-aryl moiety in high enantioselectivity (generally >90% ee). The present methods utilize a palladium catalyst supported by new (R)—H 8 -BINOL-derived monophosphine ligands. The method is applicable to a wide variety of aryl triflate substrates having variations in both electronic and steric properties. These aryl triflate substrates react with various α-alkyl (Z)- and/or (E)-0-trimethylsilyl ketene acetals in the presence of a Pd catalyst, (R)—H 8 -BINOL-derived monophosphine ligand, and a mild activator, for example, LiOAC, to provide the asymmetric α-arylation of ester compounds in high ee.

First claim

Opening claim text (preview).

What is claimed is: 1. A method of asymmetrically synthesizing an α-aryl compound of Formula I: or a pharmaceutically acceptable salt thereof, the method comprising the step of reacting a compound of Formula II with a compound of Formula III in the presence of a palladium catalyst, an activator, a compound of Formula IV, and optionally a solvent, to produce the asymmetric α-aryl compound of Formula I: wherein: * is an asymmetric carbon atom; the compound of Formula III is the (E)- or (Z)—OSiR 7 R 8 R 9 isomer; the palladium catalyst is selected from PdMe 2 (TMEDA), Pd(dba) 7 , and Pd(OAc) 2 ; the solvent is an aromatic solvent; Ar is a substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl group, which is optionally independently substituted with 1, 2 or 3 R 4 groups; is a single or double bond, wherein either all of the are single bonds or all of the are double bonds; R 1 is independently selected from hydrogen, alkyl, aryl, and arylalkyl; R 2 and R 3 are each independently selected from alkyl, cycloalkyl, aryl and arylalkyl; each R 4 is independently selected from hydrogen, amino, halogen, hydroxyl, nitro, cyano, alkyl, alkenyl, alkynyl, perfluoroalkyl, cycloalkyl, alkoxy, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, (CH 2 ) j OR 11 , (CH 2 ) j C(O)R 11 , (CH 2 ) j C(O)OR 11 , (CH 2 ) j OC(O)R 11 , (CH 2 ) j NR 12 R 13 , (CH 2 ) j C(O)NR 12 R 13 , (CH 2 ) j OC(O)NR 12 R 13 , (CH 2 ) j NR 14 C(O)R 11 , (CH 2 ) j NR 14 C(O)OR 11 , (CH 2 ) j NR 14 C(O)NR 12 R 13 , (CH 2 ) j S(O) m R 11 , and (CH 2 ) j S(O) m NR 12 R 13 , wherein each j is independently an integer selected from 0 to 6, and each m is independently an integer selected from 0 to 2; R 5 is independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heteroarylalkyl, which is optionally independently substituted with 1, 2 or 3 R 10 groups; R 6 is independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted arylalkyl, which is optionally independently substituted with 1, 2 or 3 R 10 groups; R 7 , R 8 and R 9 are each independently selected from alkyl, aryl and arylalkyl; each R 10 is independently selected from hydrogen, amino, halogen, hydroxyl, nitro, cyano, alkyl, alkenyl, alkynyl, perfluoroalkyl, cycloalkyl, alkoxy, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, (CH 2 ) j OR 11 , (CH 2 ) j C(O)R 11 , (CH 2 ) j C(O)OR 11 , (CH 2 ) j OC(O)R 11 , (CH 2 ) j NR 12 R 13 , (CH 2 ) j C(O)NR 12 R 13 , (CH 2 ) j OC(O)NR 12 R 13 , (CH 2 ) j NR 14 C(O)R 11 , (CH 2 ) j NR 14 C(O)OR 11 , (CH 2 ) j NR 14 C(O)NR 12 R 13 , (CH 2 ) j S(O) m R 11 , and (CH 2 ) j S(O) m NR 12 R 13 , wherein each j is independently an integer selected from 0 to 6, and each m is independently an integer selected from 0 to 2; R 11 is independently selected from hydrogen, alkyl, alkenyl, alkynyl, perfluoroalkyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl; and R 12 , R 13 , R 14 are each independently selected from hydrogen, alkyl, alkenyl, alkynyl, perfluoroalkyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, or R 14 is as described above, and R 12 and R 13 are joined together with the nitrogen atom to which they are attached, to form a substituted or unsubstituted 3- to 7-membered hetercycloalkyl or substituted or unsubstituted 5-membered heteroaryl, wherein the 3- to 7-membered hetercycloalkyl is selected from aziridine, azetidine, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, and azepanyl; and the 5-membered heteroaryl is selected from pyrrolyl, pyrazolyl, imidazolyl, pyridinyl, pyrazinyl, pyrimidinyl, indolyl, purinyl, benzimidazolyl, quinolinyl, and isoquinolinyl. 2. The method of claim 1 , wherein: * is an R or S asymmetric carbon atom, wherein the asymmetric α-aryl compound of Formula I is at least about 50% to about 60% enantiomeric excess; the compound of Formula III is the (E)-OSiR 7 R 8 R 9 isomer; the palladium catalyst is PdMe 2 (TMEDA); the activator is LiOC(O)CH 3 ; the aromatic solvent is selected from benzene, chlorobenzene, fluorobenzene, toluene, trifluorobenzene, dichloromethane, dichloroethane, tetrahydrofuran and mixtures thereof; Ar is a substituted or unsubstituted phenyl, substituted or unsubstituted biphenyl, substituted or unsubstituted naphthalenyl, substituted or unsubstituted benzyl, substituted or unsubstituted CH 2 (1-naphthalenyl), substituted or unsubstituted CH 2 (2-naphthalenyl), substituted or unsubstituted furanyl, substituted or unsubstituted thiophenyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted pyrazolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted pyridinyl, substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl, substituted or unsubstituted indolyl, substituted or unsubstituted purinyl, substituted or unsubstituted benzimidazolyl, substituted or unsubstituted benzo[b]thiophenyl, substituted or unsubstituted quinolinyl, and substituted or unsubstituted isoquinolinyl; R 1 is independently selected from hydrogen, (C 1 -C 6 )alkyl, phenyl, biphenyl, naphthalenyl, benzyl, CH 2 (1-naphthalenyl) and CH 2 (2-naphthalenyl); R 2 and R 3 are each independently selected from (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, phenyl, biphenyl, benzyl, and naphthalenyl; R 5 is independently selected from substituted or unsubstituted (C 1-12 )alkyl, substituted or unsubstituted phenyl, substituted or unsubstituted biphenyl, substituted or unsubstituted naphthalenyl, substituted or unsubstituted benzyl, substituted or unsubstituted CH 2 (1-naphthalenyl), substituted or unsubstituted CH 2 (2-naphthalenyl), substituted or unsubstituted furanyl, substituted or unsubstituted thiophenyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted pyrazolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted pyridinyl, substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl, substituted or unsubstituted indolyl, substituted or unsubstituted purinyl, substituted or unsubstituted benzimidazolyl, substituted or unsubstituted benzo[b]thiophenyl, substituted or unsubstituted quinolinyl, substituted or unsubstituted isoquinolinyl, substituted or unsubstituted aziridine, substituted or unsubstituted oxiranyl, substituted or unsubstituted thiiranyl, substituted or unsubstituted azetidinyl, substituted or unsubstituted oxetanyl, substituted or unsubstituted thietanyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted pyrazolidinyl, substituted or unsubstituted imidazolidinyl, substituted or unsubstituted oxolanyl, substituted or unsubstituted thiolanyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted oxanyl, substituted or unsubstituted thianyl, substituted or unsubstituted piperazinyl, substituted or unsubstituted morpholinyl, substituted or unsubstituted thiomorpholinyl, substituted or unsubstituted azepanyl, substituted or unsubstituted oxepanyl, and substituted or unsubstituted thiepinyl; R 6 is independently selected from hydrogen, substituted or unsubstituted (C 1 -C 6 )alkyl, substituted or unsubs

Assignees

Inventors

Classifications

  • Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a ring other than a six-membered aromatic ring in the acid moiety · CPC title

  • Aromatic phosphine oxides or thioxides (P-C aromatic linkage) · CPC title

  • Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title

  • Ethers · CPC title

  • by reduction of pentavalent phosphorus derivatives, e.g. -P=X with X = O, S, Se or -P-Hal2 · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9512155B2 cover?
The disclosure provides new and improved methods for the Pd-catalyzed asymmetric α-arylation of ester compounds, which produce the corresponding α-aryl moiety in high enantioselectivity (generally >90% ee). The present methods utilize a palladium catalyst supported by new (R)—H 8 -BINOL-derived monophosphine ligands. The method is applicable to a wide variety of aryl triflate substrates having …
Who is the assignee on this patent?
Zhou Steve Jianrong, Huang Zhiyan, Univ Nanyang Tech
What technology area does this patent fall under?
Primary CPC classification C07F9/5022. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Dec 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).